OSE Immunotherapeutics

OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis). • Anti-SIRPα mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and combo; Phase 2 in CRM diseases planned end 2024. • ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. 4 proprietary drug discovery platforms • Pro-resolutive mAb platform • Myeloid Checkpoint platform • BiCKI® Platform • mRNA Therapeutic platform f